The Bell2Bell (B2B) Podcast

LOS ANGELES, September 24, 2024 (GLOBE NEWSWIRE) – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Vladi Delsoglio, CEO of Ederra, a farm-to-body wellness brand that combines nature and cutting-edge science to create innovative, functional supplements for brain and body longevity.

To begin the interview, Delsoglio discussed his personal journey and how it led to the founding of Ederra.

“I started Ederra after being diagnosed with fatty liver disease, when I realized that traditional treatments weren't enough. When the doctor told me that I had a non-alcoholic fatty liver disease, it was a shock to me. I’ve always had an amazing, healthy lifestyle – no smoking, drinking one or two beers per week and cooking all my meals. My doctor suggested that I incorporate broccoli microgreens into my diet. When I did that, my liver got better. From there, I start chatting with doctors, scientists and farmers in San Diego County. A year later, we launched EMPWR+, Ederra’s flagship product.”

“The name of the company, Ederra, comes from a Basque word meaning that everything surrounding you is beautiful. When you are happy with yourself, when you are healthy, when you have a healthy lifestyle, then everything surrounding you is beautiful. The EMPWR+ brand is named for the extra kick it gives to your daily routine. Our tagline is ‘Your wellness, your routine, your way’.”

“EMPWR+ is a farm-to-body functional superfood supplement featuring broccoli microgreens and Lion’s Mane mushrooms. Broccoli has a very potent antioxidant longevity compound called sulforaphane. Inside the broccoli microgreens featured in EMPWR+, this compound is 50 to 100 times more potent. It’s super powerful and really helps on anti-inflammatory, detox, anti-cancer and so forth. We add Lion’s Mane mushrooms for brain health. We wanted to create a very simple, two-ingredient, super powerful supplement that helps your body as well as your brain.”

Join IBN’s Carmel Fisher and Vladi Delsoglio, CEO of Ederra, to learn more about the company’s farm-to-body approach to its products and how that approach differentiates Ederra in the supplement industry.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Ederra

Ederra creates farm-to-body functional superfood supplements designed to help people live healthier, more vibrant lives. The company caters to visionaries, entrepreneurs, explorers and those who push boundaries. Ederra’s products also serve our most cherished individuals – sisters, brothers, friends and mothers.

Ederra tackles challenges with diverse perspectives, unified by a shared passion for nutrition, sustainability and making the world a better place. To deliver the quality supplements its customers deserve, Ederra revolutionized production through local neighbor farms. The company’s dedication to freshness, quality and sustainability isn’t just about being premium; it’s about making a positive impact on the world.

For more information, visit the company’s website at www.EderraLyfe.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

LOS ANGELES, September 24, 2024 (GLOBE NEWSWIRE) – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Vladi Delsoglio, CEO of Ederra, a farm-to-body wellness brand that combines nature and cutting-edge science to create innovative, functional supplements for brain and body longevity.

To begin the interview, Delsoglio discussed his personal journey and how it led to the founding of Ederra.

“I started Ederra after being diagnosed with fatty liver disease, when I realized that traditional treatments weren't enough. When the doctor told me that I had a non-alcoholic fatty liver disease, it was a shock to me. I’ve always had an amazing, healthy lifestyle – no smoking, drinking one or two beers per week and cooking all my meals. My doctor suggested that I incorporate broccoli microgreens into my diet. When I did that, my liver got better. From there, I start chatting with doctors, scientists and farmers in San Diego County. A year later, we launched EMPWR+, Ederra’s flagship product.”

“The name of the company, Ederra, comes from a Basque word meaning that everything surrounding you is beautiful. When you are happy with yourself, when you are healthy, when you have a healthy lifestyle, then everything surrounding you is beautiful. The EMPWR+ brand is named for the extra kick it gives to your daily routine. Our tagline is ‘Your wellness, your routine, your way’.”

“EMPWR+ is a farm-to-body functional superfood supplement featuring broccoli microgreens and Lion’s Mane mushrooms. Broccoli has a very potent antioxidant longevity compound called sulforaphane. Inside the broccoli microgreens featured in EMPWR+, this compound is 50 to 100 times more potent. It’s super powerful and really helps on anti-inflammatory, detox, anti-cancer and so forth. We add Lion’s Mane mushrooms for brain health. We wanted to create a very simple, two-ingredient, super powerful supplement that helps your body as well as your brain.”

Join IBN’s Carmel Fisher and Vladi Delsoglio, CEO of Ederra, to learn more about the company’s farm-to-body approach to its products and how that approach differentiates Ederra in the supplement industry.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Ederra

Ederra creates farm-to-body functional superfood supplements designed to help people live healthier, more vibrant lives. The company caters to visionaries, entrepreneurs, explorers and those who push boundaries. Ederra’s products also serve our most cherished individuals – sisters, brothers, friends and mothers.

Ederra tackles challenges with diverse perspectives, unified by a shared passion for nutrition, sustainability and making the world a better place. To deliver the quality supplements its customers deserve, Ederra revolutionized production through local neighbor farms. The company’s dedication to freshness, quality and sustainability isn’t just about being premium; it’s about making a positive impact on the world.

For more information, visit the company’s website at www.EderraLyfe.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer’s Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN’s ongoing efforts to provide specialized content distribution via widespread syndication channels.

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.

“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”

Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is excited to announce the release of the latest episode of The Bell2Bell Podcast, recorded live from the Alzheimer’s Association International Conference® 2024 (AAIC®) in Philadelphia. This release is part of IBN’s ongoing efforts to provide specialized content distribution via widespread syndication channels.

The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Dr. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.

“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”

Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Bell2Bell’s latest podcast features Joe Onyero, Founder and CEO of Bebuzee Inc. (OTC: BBUZ), a social platform and streaming service focused on development and deployment of America's first superapp.

To begin the interview, Onyero introduced Bebuzee’s business model.

“Bebuzee is going to be launching the first superapp in the U.S. and Europe,” he said. “I'm sure a lot of people don't understand what I mean when I say superapp, so I’ll give an example. In Asia, they have a superapp called WeChat. It has a market cap of over $300 billion. The app has everything. Most social media users have video sharing apps, messaging apps and different sorts of apps on their phones. What a superapp does is give you one app that covers everything.”

“Instead of downloading 15-20 apps, you can have one superapp that does everything. It makes it easier. People are tired of jumping from one app to another. Bebuzee’s super app is going to do almost everything for you; it’s incredible. We’ve just finished it, and we’re preparing and getting all the infrastructure ready to launch globally.”

Onyero then discussed his background prior to founding Bebuzee.

“I have been in the social media industry for a very long time. In 2004, seven of my friends and I created a messaging service in Cambridge, U.K., but we didn’t launch it. After a couple of years, one of the big social media platforms in the U.S. launched something similar to what we created two years before. We were kicking ourselves. In 2012, I started putting ideas together, something that I see as the modern-day social networking platform. That was when Bebuzee was born… A superapp is very difficult to develop, but we never anticipated that it would take this long. That’s why we're so delighted that the superapp was completed at the end of 2023. That's a huge achievement.”

Join IBN’s Stuart Smith and Joe Onyero, Founder and CEO of Bebuzee Inc., to learn more about the company’s recent milestones, as well as its operational goals for the balance of 2024 and beyond.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

Bell2Bell’s latest podcast features Joe Onyero, Founder and CEO of Bebuzee Inc. (OTC: BBUZ), a social platform and streaming service focused on development and deployment of America's first superapp.

To begin the interview, Onyero introduced Bebuzee’s business model.

“Bebuzee is going to be launching the first superapp in the U.S. and Europe,” he said. “I'm sure a lot of people don't understand what I mean when I say superapp, so I’ll give an example. In Asia, they have a superapp called WeChat. It has a market cap of over $300 billion. The app has everything. Most social media users have video sharing apps, messaging apps and different sorts of apps on their phones. What a superapp does is give you one app that covers everything.”

“Instead of downloading 15-20 apps, you can have one superapp that does everything. It makes it easier. People are tired of jumping from one app to another. Bebuzee’s super app is going to do almost everything for you; it’s incredible. We’ve just finished it, and we’re preparing and getting all the infrastructure ready to launch globally.”

Onyero then discussed his background prior to founding Bebuzee.

“I have been in the social media industry for a very long time. In 2004, seven of my friends and I created a messaging service in Cambridge, U.K., but we didn’t launch it. After a couple of years, one of the big social media platforms in the U.S. launched something similar to what we created two years before. We were kicking ourselves. In 2012, I started putting ideas together, something that I see as the modern-day social networking platform. That was when Bebuzee was born… A superapp is very difficult to develop, but we never anticipated that it would take this long. That’s why we're so delighted that the superapp was completed at the end of 2023. That's a huge achievement.”

Join IBN’s Stuart Smith and Joe Onyero, Founder and CEO of Bebuzee Inc., to learn more about the company’s recent milestones, as well as its operational goals for the balance of 2024 and beyond.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

Bell2Bell’s latest podcast features Dr. Michael Dent, Founder, CEO and Chairman of HealthLynked Corp. (OTCQB: HLYK), a trailblazer in healthcare technology.

To begin the interview, Dent introduced HealthLynked’s business model.

“HealthLynked is a pioneering healthcare technology company focused on improving the efficiency and quality of healthcare through our advanced, integrated platform,” Dent said. “Our business model revolves around creating a global healthcare network that leverages artificial intelligence and an extensive healthcare dataset to provide personalized healthcare recommendations and streamline patient/provider interactions.”

“We offer an array of services, including online medical record storage, appointment scheduling, telemedicine and patient engagement tools. Our platform is designed to facilitate the exchange of medical information among healthcare practices, hospitals and emergency rooms, making it more accessible and efficient to both patients and providers.”

Dent then discussed his background prior to founding HealthLynked.

“I'm a physician by training… I attended medical school at the University of South Carolina in Charleston and then went on to my residency in obstetrics and gynecology at the University of Texas in Galveston. I came to Naples, Florida, where I started my practice focused mostly on high-risk obstetrics and minimally invasive surgery… In early 2001, I started a company called NeoGenomics Laboratories based in cancer diagnostics around genomics. I was the CEO many years there, and that became a global cancer diagnostics laboratory. I then founded HealthLynked, which is in the healthcare AI space, looking at how we can really improve healthcare for everybody globally around the world.”

Join IBN’s Stuart Smith and Dr. Michael Dent, Founder, CEO and Chairman of HealthLynked Corp., to learn more about HealthLynked’s recent milestones and the issues it’s addressing in the global healthcare industry.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Bell2Bell’s latest podcast features Dr. Michael Dent, Founder, CEO and Chairman of HealthLynked Corp. (OTCQB: HLYK), a trailblazer in healthcare technology.

To begin the interview, Dent introduced HealthLynked’s business model.

“HealthLynked is a pioneering healthcare technology company focused on improving the efficiency and quality of healthcare through our advanced, integrated platform,” Dent said. “Our business model revolves around creating a global healthcare network that leverages artificial intelligence and an extensive healthcare dataset to provide personalized healthcare recommendations and streamline patient/provider interactions.”

“We offer an array of services, including online medical record storage, appointment scheduling, telemedicine and patient engagement tools. Our platform is designed to facilitate the exchange of medical information among healthcare practices, hospitals and emergency rooms, making it more accessible and efficient to both patients and providers.”

Dent then discussed his background prior to founding HealthLynked.

“I'm a physician by training… I attended medical school at the University of South Carolina in Charleston and then went on to my residency in obstetrics and gynecology at the University of Texas in Galveston. I came to Naples, Florida, where I started my practice focused mostly on high-risk obstetrics and minimally invasive surgery… In early 2001, I started a company called NeoGenomics Laboratories based in cancer diagnostics around genomics. I was the CEO many years there, and that became a global cancer diagnostics laboratory. I then founded HealthLynked, which is in the healthcare AI space, looking at how we can really improve healthcare for everybody globally around the world.”

Join IBN’s Stuart Smith and Dr. Michael Dent, Founder, CEO and Chairman of HealthLynked Corp., to learn more about HealthLynked’s recent milestones and the issues it’s addressing in the global healthcare industry.

To hear the episode and subscribe for future podcasts, visit https://podcast.bell2bell.com.

The latest installment of The Bell2Bell Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

The Bell2Bell’s latest audio production features Stormer Santana, Director of Sales for Dalmore Group, a tech-driven investment bank and broker dealer on a mission to revolutionize the way companies raise capital online.

 

To begin the interview, Santana discussed his reasons for working with Dalmore Group.

 

“We focus on online fundraising. So, as Director of Sales at Dalmore, I have the opportunity to work with hundreds of founders on a quarterly and annual basis. For me, the why is really being able to work with passionate entrepreneurs,” Santana said. “Being able to hear the story and the purpose and the issuer’s why gets me really excited.”

 

Santana then discussed how companies are raising capital online in the current environment.

 

“We've been a broker dealer for 20 years now, hyper focused in online fundraising, and that was really started through the JOBS Act, which introduced Regulation Crowdfunding (Reg CF), Regulation A+ and then, of course, Regulation D. Reg CF allows you to raise up to $5 million in capital from anyone over the age of 18 – both accredited and non-accredited investors can participate. The general population typically doesn't have access to these private investment opportunities. So, now, what we're finding is that these issuers are leveraging these tools to go out to the masses, raise capital in volume from the crowd and really bring on a sense of community.”

 

“Then, there’s Reg A+, which allows you to raise up to $75 million in capital. That’s really our focus at Dalmore. We've been fortunate enough to participate with some of the really significant offerings in the U.S. and over 50% of all Reg A+ filings, per KingsCrowd. Finally, there's Reg D, which is reserved for accredited investors only. Of course, that's a very popular and common path to raise capital. Some of our issuers are leveraging CF, A+ and D concurrently in different strategies. At a high level, those are some of the exemptions that we're focused on and how issuers are leveraging them.”

 

Join IBN’s Jonathan Keim and Bell2Bell’s latest guest to learn more about the ways that issuers can increase the cost-effectiveness and predictability of the capital raising process.

 

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

The Bell2Bell’s latest audio production features Stormer Santana, Director of Sales for Dalmore Group, a tech-driven investment bank and broker dealer on a mission to revolutionize the way companies raise capital online.

 

To begin the interview, Santana discussed his reasons for working with Dalmore Group.

 

“We focus on online fundraising. So, as Director of Sales at Dalmore, I have the opportunity to work with hundreds of founders on a quarterly and annual basis. For me, the why is really being able to work with passionate entrepreneurs,” Santana said. “Being able to hear the story and the purpose and the issuer’s why gets me really excited.”

 

Santana then discussed how companies are raising capital online in the current environment.

 

“We've been a broker dealer for 20 years now, hyper focused in online fundraising, and that was really started through the JOBS Act, which introduced Regulation Crowdfunding (Reg CF), Regulation A+ and then, of course, Regulation D. Reg CF allows you to raise up to $5 million in capital from anyone over the age of 18 – both accredited and non-accredited investors can participate. The general population typically doesn't have access to these private investment opportunities. So, now, what we're finding is that these issuers are leveraging these tools to go out to the masses, raise capital in volume from the crowd and really bring on a sense of community.”

 

“Then, there’s Reg A+, which allows you to raise up to $75 million in capital. That’s really our focus at Dalmore. We've been fortunate enough to participate with some of the really significant offerings in the U.S. and over 50% of all Reg A+ filings, per KingsCrowd. Finally, there's Reg D, which is reserved for accredited investors only. Of course, that's a very popular and common path to raise capital. Some of our issuers are leveraging CF, A+ and D concurrently in different strategies. At a high level, those are some of the exemptions that we're focused on and how issuers are leveraging them.”

 

Join IBN’s Jonathan Keim and Bell2Bell’s latest guest to learn more about the ways that issuers can increase the cost-effectiveness and predictability of the capital raising process.

 

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer